跳至主要内容
临床试验/NCT01144832
NCT01144832已完成4 期

IBS Treatment With H1-receptor Antagonists

KU Leuven1 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
KU Leuven
入组人数
55
试验地点
1
主要终点
Effect of treatment on visceral sensitivity measured with rectal barostat.

研究概览

简要总结

Purpose:

To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.

Design:

Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

End points:

End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Irritable Bowel Syndrome (ROME III criteria)
  • age 18-65 years

排除标准

  • medication: antidepressants or H1-receptor antagonists
  • pregnancy, breast feeding
  • co-morbidity: severe kidney- and/or liver disease

研究组 & 干预措施

placebo capsule

Placebo Comparator

干预措施: placebo capsule (Drug)

ebastine

Active Comparator

干预措施: ebastine (Drug)

结局指标

主要结局

Effect of treatment on visceral sensitivity measured with rectal barostat.

时间窗: after 12 weeks treatment

次要结局

  • Effect of treatment on IBS symptoms.(after 12 weeks treatment)

研究者

发起方
KU Leuven
申办方类型
Other
责任方
Principal Investigator
主要研究者

Guy Boeckxstaens

Prof. Dr.

KU Leuven

研究点 (1)

Loading locations...

相似试验